A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer (including metastatic breast cancer), and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.